热门资讯> 正文

BridgeBio计划于2033年发行5.5亿美元可转换票据

2026-01-15 05:09

BridgeBio Pharma(BBIO) 0

BridgeBio Pharma (BBIO) on Wednesday said it plans to offer $550 million of convertible senior notes due 2033 in a private placement to qualified institutional buyers.
The company said it expects to grant initial purchasers an option to buy up to an additional $82.5 million of notes.
Net proceeds are intended to be used to repurchase, settle conversion obligations related to, or repay at maturity a portion of its 2.50% convertible senior notes due 2027, as well as for general corporate purposes.
BridgeBio also said it plans to use up to $82.5 million of cash on hand to repurchase shares from certain note purchasers in privately negotiated transactions concurrent with the pricing of the notes.

BBIO -4.00% after hours to $74.64.
Source: Press Release

More on BridgeBio Pharma

BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study - Slideshow
BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue
BridgeBio succeeds in late-stage encaleret study

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。